Seegakula Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 9.47 M
as on 17-12-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 6.91 Cr
as on 17-12-2024
- Revenue 113.08%
(FY 2020)
- Profit 11.03%
(FY 2020)
- Ebitda 5.73%
(FY 2020)
- Net Worth -291.33%
(FY 2020)
- Total Assets -0.89%
(FY 2020)
About Seegakula Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.47 M.
The company currently has active open charges totaling ₹6.91 Cr.
Seegakula Setty, Sujatha Sathyanarayana, Manoj Nagaraj, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232KA2007PTC042292
- Company No.
042292
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Mar 2007
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Seegakula Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hariharan Sakthivel  | Director | 29-Jan-2018 | Current |
| Seegakula Setty | Director | 29-Mar-2007 | Current |
| Sujatha Sathyanarayana | Director | 29-Mar-2007 | Current |
| Manoj Nagaraj | Director | 29-Jan-2018 | Current |
Financial Performance of Seegakula Pharmaceuticals.
Seegakula Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 113.08% increase. The company also saw a substantial improvement in profitability, with a 11.03% increase in profit. The company's net worth observed a substantial decline by a decrease of 291.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Seegakula Pharmaceuticals?
In 2020, Seegakula Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 29 Aug 2016 | ₹6.91 Cr | Open |
How Many Employees Work at Seegakula Pharmaceuticals?
Seegakula Pharmaceuticals has a workforce of 2 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Seegakula Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Seegakula Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
